PGNYProgyny, Inc. Common Stock — stock analysis & sentiment

At $26.86, the stock sits a little under two-thirds of the way up a 52-week band that runs from $16.10 to $33.065 — a range whose high is roughly double its low. That width matters more than the current position: a stock that has covered that much ground in a year has been repriced substantially in both directions rather than drifting, and the current level is closer to the top of the band than the bottom without being near either edge.

The market values the business around $2.0 billion, or about 28.5 times trailing earnings and 4.4 times book value. The gap between that trailing multiple and the forward figure of roughly 11.3 is the most striking thing in the valuation data — it reflects earnings expectations well above what the past twelve months delivered, so the two multiples describe quite different pictures of the same price. Actual profitability is thin: a net margin near 6% on revenue growing about 5.3%, meaning the company converts a modest slice of sales into profit and is expanding at a single-digit pace. A beta of 0.991 puts its day-to-day movement essentially in line with the broad market, despite the wide annual range.

Recent headlines are light on operating news. Much of the flow is calendar and administrative — announcements of quarterly results dates and appearances at the Canaccord Genuity and BofA Securities health care conferences. The items with more substance concern insider activity in opposite directions: coverage of the CEO's $1.9 million purchase in December 2025 and, six months later, commentary on a share sale by the CFO. The remainder is third-party comparison writing that places the stock against healthcare peers, including a value screen against CRL and a piece centered on Concentra rather than on this company, so part of the attention it has drawn is sector framing rather than company-specific developments.